Navigation Links
BARC Central Laboratory Joins Alzheimer's Association Research Roundtable
Date:3/30/2009

- Global Laboratory's Technology Transfer Expertise to Support Biomarker Translational Research -

NEW YORK, March 30 /PRNewswire/ -- Biomarkers have become increasingly important to Alzheimer's disease research as a method for risk assessment, early detection, testing new therapies and eventual early intervention with better drugs once they are developed. As part of its ongoing research and development of biomarkers for Alzheimer's and other diseases, BARC Central Laboratory is pleased to announce it has joined the Alzheimer's Association Research Roundtable. As a Sponsor, BARC will be participating in the Roundtable presentations and related subcommittee meetings, with particular focus on the evolution of biochemical biomarkers as prognostic and diagnostic indicators.

A biomarker is a substance or characteristic that can be objectively measured and evaluated as an indicator of normal body processes, disease processes, or the body's response(s) to a therapeutic intervention.

It is widely believed that Alzheimer's disease brain changes, including amyloid plaques and neurofibrillary tangles, begin many years before symptoms are evident or there is significant death of brain cells. It is critical to identify affected individuals while they are still cognitively normal so that future disease modifying therapies can preserve normal function. The testing and eventual use of such therapies requires identification of affected and "at risk" individuals in order to steer them to clinical trials, and to direct and monitor therapy.

"Alzheimer's disease is without question a growing epidemic and major public health concern. The Alzheimer's Association is the preeminent U.S. voluntary health organization in the research community's drive to eradicate Alzheimer's disease, and BARC looks forward to advancing early detection and treatment for Alzheimer's in partnership with the Alzheimer's Association and other Research Roundtable member companies," said Rudi Marien, CEO of the BARC Group.

"Discovery of measurable markers that track with the presence of Alzheimer's pathology and that predict the development of cognitive decline in people who are still cognitively normal, known as 'antecedent biomarkers,' are especially needed," said William Thies, PhD, Chief Medical & Scientific Officer at the Alzheimer's Association. "We are very pleased that BARC has chosen to become part of the Research Roundtable, and look forward to their valuable contributions to the group."

The Alzheimer's Association Research Roundtable is a consortium of scientists from the pharmaceutical, biotech, diagnostics, imaging and cognitive testing industries along with Association staff and advisors. The Research Roundtable's mission is to facilitate the development and implementation of new treatments for Alzheimer's disease by collectively addressing obstacles to research and development, clinical care, and public health education.

About BARC

Bio Analytical Research Corporation (BARC) is a leading global central laboratory and is currently running 400 different protocols involving more than 8,000 investigators worldwide. Our experience involves all major therapeutic areas including neurology, infectious disease, diabetes, osteoporosis, cardiovascular, gastroenterology, oncology, endocrinology, respiratory, dermatology and immunology. BARC performs more than 2,000 assays, including molecular diagnostics and genomics, and serves as a technology transfer channel by developing and clinically validating new laboratory tests on a global, multi-site GCP-certified platform for pharmaceutical and biotechnology companies worldwide. For more information, call (516) 719-1052 or visit www.barclab.com.

About the Alzheimer's Association

The Alzheimer's Association, the nonprofit world leader in Alzheimer's research and support, is the first and largest U.S. voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer's. For more than 25 years, the donor-supported Alzheimer's Association has provided reliable information and care consultation; created supportive services for families; increased funding for dementia research; and influenced public policy changes. For more information, call (800) 272-3900 or visit www.alz.org.

CONTACT:

BARC USA: Nele Langenaken, (516) 719-1052, nele.langenaken@barcusa.com


'/>"/>
SOURCE BARC Central Laboratory
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
2. Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in Californias Central Valley
3. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
4. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
5. deCODE Receives California Clinical Laboratory License
6. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
7. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
8. Eating Walnuts Slows Cancer Growth, Laboratory Study Finds
9. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
10. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
11. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):